Alembic Pharmaceuticals Limited (APLLTD.NS)
INR 1045.0
(-1.06%)
INR 1045.0
(-1.06%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Revenue | 61.12 Billion | 56.52 Billion | 52.31 Billion | 52.76 Billion | 44.91 Billion | 38.06 Billion |
| Cost of Revenue | 34.34 Billion | 17.08 Billion | 17.23 Billion | 15.21 Billion | 13.14 Billion | 11.93 Billion |
| Gross Profit | 26.78 Billion | 39.43 Billion | 35.08 Billion | 37.54 Billion | 31.77 Billion | 26.13 Billion |
| Operating Expenses | 15.86 Billion | 35.1 Billion | 29.16 Billion | 24.58 Billion | 20.66 Billion | 18.55 Billion |
| Selling, General and Administrative Expenses | 12.48 Billion | 11.93 Billion | 11.01 Billion | 9.04 Billion | 6.86 Billion | 7.25 Billion |
| Research and Development Expenses | 4.74 Billion | 290.7 Million | 505.9 Million | 253.8 Million | 426.4 Million | 302.7 Million |
| Other Expenses | 283.1 Million | 27.4 Million | 1.3 Million | 2 Million | 200 Thousand | 2.3 Million |
| Cost and Expenses | 55.46 Billion | 52.19 Billion | 46.39 Billion | 39.79 Billion | 33.81 Billion | 30.49 Billion |
| Operating Income | 5.75 Billion | 4.37 Billion | 5.87 Billion | 12.96 Billion | 11.11 Billion | 7.41 Billion |
| Interest Expense | 561.9 Million | 501.7 Million | 177.3 Million | 160.2 Million | 271.6 Million | 184.1 Million |
| Income Tax Expense | 160 Million | 126.1 Million | 1.04 Billion | 2.53 Billion | 1.99 Billion | 1.56 Billion |
| Earnings before Tax | 6.31 Billion | 3.54 Billion | 6.2 Billion | 13.68 Billion | 9.99 Billion | 7.49 Billion |
| Net Income | 6.15 Billion | 3.41 Billion | 5.2 Billion | 11.46 Billion | 8.28 Billion | 5.84 Billion |
| Earnings Per Share Basic | 31.33 | 17.40 | 26.50 | 59.18 | 43.97 | 31.00 |
| Earnings Per Share Diluted | 31.33 | 17.40 | 26.50 | 59.18 | 43.97 | 31.00 |
| Weighted Average Shares Outstanding | 196.55 Million | 196.56 Million | 196.56 Million | 193.74 Million | 188.51 Million | 188.51 Million |
| Weighted Average Shares Outstanding (Diluted) | 196.56 Million | 196.56 Million | 196.56 Million | 193.74 Million | 188.51 Million | 188.51 Million |
| Gross Margin | 0.44 | 0.70 | 0.67 | 0.71 | 0.71 | 0.69 |
| EBIT Margin | 0.16 | 0.12 | 0.18 | 0.30 | 0.27 | 0.24 |
| Profit Margin | 0.10 | 0.06 | 0.10 | 0.22 | 0.18 | 0.15 |
| EBITDA | 9.61 Billion | 7.11 Billion | 9.24 Billion | 15.67 Billion | 11.84 Billion | 8.82 Billion |
| Earnings Before Tax Margin | 0.09 | 0.08 | 0.11 | 0.25 | 0.25 | 0.19 |
| Breakdown | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 | 2023 Q1 |
|---|---|---|---|---|---|---|
| Revenue | 15.61 Billion | 15.16 Billion | 62.28 Billion | 16.3 Billion | 15.94 Billion | 14.86 Billion |
| Cost of Revenue | 8.42 Billion | 8.5 Billion | 34.34 Billion | 4.6 Billion | 4.61 Billion | 4.13 Billion |
| Gross Profit | 7.18 Billion | 6.66 Billion | 27.94 Billion | 11.69 Billion | 11.33 Billion | 10.72 Billion |
| Operating Expenses | 5.51 Billion | 4.75 Billion | 21.33 Billion | 9.72 Billion | 9.92 Billion | 9.4 Billion |
| Selling, General and Administrative Expenses | 5.51 Billion | 4.75 Billion | - | 4.39 Billion | 4.57 Billion | 3.48 Billion |
| Research and Development Expenses | - | 843.6 Million | - | 1.14 Billion | 1.21 Billion | 1.17 Billion |
| Other Expenses | 21 Million | 36 Million | 283.1 Million | 28.9 Million | 101.5 Million | 116.7 Million |
| Cost and Expenses | 13.93 Billion | 13.26 Billion | 55.67 Billion | 14.33 Billion | 14.54 Billion | 13.53 Billion |
| Operating Income | 1.67 Billion | 1.9 Billion | 6.6 Billion | 1.99 Billion | 1.5 Billion | 1.32 Billion |
| Interest Expense | 131.8 Million | 109.4 Million | 561.9 Million | 151.7 Million | 156.9 Million | 143.9 Million |
| Income Tax Expense | 224.9 Million | 46.4 Million | 160 Million | 41.3 Million | -19.2 Million | 91.5 Million |
| Earnings before Tax | 1.56 Billion | 1.83 Billion | 6.32 Billion | 1.84 Billion | 1.34 Billion | 1.29 Billion |
| Net Income | 1.34 Billion | 1.78 Billion | 6.15 Billion | 1.8 Billion | 1.36 Billion | 1.2 Billion |
| Earnings Per Share Basic | 6.85 | 9.07 | - | 9.18 | 6.95 | 6.14 |
| Earnings Per Share Diluted | 6.85 | 9.07 | - | 9.18 | 6.95 | 6.14 |
| Weighted Average Shares Outstanding | 196.56 Million | 196.55 Million | 196.55 Million | 196.56 Million | 196.56 Million | 196.56 Million |
| Weighted Average Shares Outstanding (Diluted) | 196.56 Million | 196.55 Million | 196.55 Million | 196.56 Million | 196.56 Million | 196.56 Million |
| Gross Margin | 0.46 | 0.44 | 0.45 | 0.72 | 0.71 | 0.72 |
| EBIT Margin | 0.15 | 0.17 | - | 0.17 | 0.14 | 0.14 |
| Profit Margin | 0.09 | 0.12 | 0.10 | 0.11 | 0.09 | 0.08 |
| EBITDA | 2.36 Billion | 2.6 Billion | - | 2.69 Billion | 2.17 Billion | 2.1 Billion |
| Earnings Before Tax Margin | 0.11 | 0.13 | 0.11 | 0.12 | 0.09 | 0.09 |
RYR
SLMXF
EM
RVNL
CNMA
1900